Jesús María
Hernández Rivas
Catedrático de Universidad
Hospital de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital de Gran Canaria Dr. Negrin (10)
2024
-
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial
Haematologica, Vol. 109, Núm. 2, pp. 543-552
-
Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
HemaSphere
-
The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis
American Journal of Hematology
2023
-
Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases
Frontiers in immunology, Vol. 14, pp. 1310211
-
Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
HemaSphere, Vol. 7, Núm. 1, pp. E818
2022
-
Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis
British Journal of Haematology, Vol. 199, Núm. 4, pp. 529-538
-
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain
Leukemia and Lymphoma
2021
-
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome–negative adult lymphoblastic leukemia
Blood, Vol. 137, Núm. 14, pp. 1879-1894
2020
-
miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk
Leukemia, Vol. 34, Núm. 10, pp. 2648-2659
2011
-
Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia
Haematologica, Vol. 96, Núm. 10, pp. 1448-1456